Investigación / Grupos de investigación

Grupo  602

Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Publicaciones (898)

  • Metro, G; Addeo, A; Signorelli, D; Gili, A; Economopoulou, P; Roila, F; Banna, G; De Toma, A; Cobo, JR; Camerini, A; Christopoulou, A; Lo Russo, G; Banini, M; Galetta, D; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Garassino, MC; Mountzios, G.

    Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort

    Journal of Thoracic Disease. 2019; 11(12): 4972-4981 Nº de citas: 44 [doi:10.21037/jtd.2019.12.23]

  • Perez, EA; Barrios, C; Eiermann, W; Toi, M; Im, YH; Conte, P; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Petersen, JA; De Haas, S; Hoersch, S; Patre, M; Ellis, PA.

    Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE

    CANCER. 2019; 125(22): 3974-3984 Nº de citas: 94 [doi:10.1002/cncr.32392]

  • Hollern, DP; Xu, N; Thennavan, A; Glodowski, C; Garcia-Recio, S; Mott, KR; He, XP; Garay, JP; Carey-Ewend, K; Marron, D; Ford, J; Liu, SY; Vick, SC; Martin, M; Parker, JS; Vincent, BG; Serody, JS; Perou, CM.

    B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

    CELL. 2019; 179(5): 1191 Nº de citas: 387 [doi:10.1016/j.cell.2019.10.028]

  • Benavides, M; Diaz-Rubio, E; Carrato, A; Abad, A; Guillen, C; Garcia-Alfonso, P; Gil, S; Cano, MT; Safont, MJ; Gravalos, C; Manzano, JL; Sanchez, A; Alcaide, J; Lopez, R; Massuti, B; Sastre, J; Martinez, E; Escudero, P; Mendez, M; Aranda, E.

    Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open. 2019; 4(6): Nº de citas: 15 [doi:10.1136/esmoopen-2019-000599]

  • Schadendorf, D; Ascierto, PA; Haanen, J; Espinosa, E; Demidov, L; Garbe, C; Guida, M; Lorigan, P; Chiarion-Sileni, V; Gogas, H; Maio, M; Fierro, MT; Hoeller, C; Terheyden, P; Gutzmer, R; Guren, TK; Bafaloukos, D; Rutkowski, P; Plummer, R; Waterston, A; Kaatz, M; Mandala, M; Marquez-Rodas, I; Munoz-Couselo, E; Dummer, R; Grigoryeva, E; Young, TC; Nathan, P.

    Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

    EUROPEAN JOURNAL OF CANCER. 2019; 121: 144-153 Nº de citas: 33 [doi:10.1016/j.ejca.2019.08.014]

  • Pascual, JMA; Hernandez, JAF; Fernandez, GB; Casares, CM; Alvarez, RA; Anzorena, BF; Borbalas, AL; Blanco, MR; Blazquez, SC; Raventos, VA.

    Update in pelvic and retroperitoneal sarcoma management: The role of compartment surgery

    CIRUGIA ESPANOLA. 2019; 97(9): 480-488 Nº de citas: 8 [doi:10.1016/j.ciresp.2019.06.011]

  • Carmona-Bayonas, A; Jimenez-Fonseca, P; Garrido, M; Custodio, A; Hernandez, R; Lacalle, A; Cano, JM; Aguado, G; de Castro, EM; Mancenido, FA; Macias, I; Visa, L; Richard, MM; Mangas, M; Canovas, MS; Longo, F; Rey, LI; Lago, NM; Carnicero, AM; Sanchez, A; Azkarate, A; Limon, ML; Perez, CH; Ramchandani, A; Pimentel, P; Cerda, P; Serrano, R; Gil-Negrete, A; Marin, M; Hurtado, A; Bayona, RS; Gallego, J.

    Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer

    THROMBOSIS AND HAEMOSTASIS. 2019; 119(11): 1849-1859 Nº de citas: 24 [doi:10.1055/s-0039-1694012]

  • Kopetz, S; Grothey, A; Yaeger, R; Van Cutsem, E; Desai, J; Yoshino, T; Wasan, H; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Pfeiffer, P; Orlov, S; Lonardi, S; Elez, E; Kim, TW; Schellens, JHM; Guo, C; Krishnan, A; Dekervel, J; Morris, V; Ferrandiz, AC; Tarpgaard, LS; Braun, M; Gollerkeri, A; Keir, C; Maharry, K; Pickard, M; Christy-Bittel, J; Anderson, L; Sandor, V; Tabernero, J.

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    NEW ENGLAND JOURNAL OF MEDICINE. 2019; 381(17): 1632-1643 Nº de citas: 1194 [doi:10.1056/NEJMoa1908075]

  • Larkin, J; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Hogg, D; Hill, A; Marquez-Rodas, I; Haanen, J; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bastholt, L; Rizzo, JI; Balogh, A; Moshyk, A; Hodi, FS; Wolchok, JD.

    Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    NEW ENGLAND JOURNAL OF MEDICINE. 2019; 381(16): 1535-1546 Nº de citas: 2984 [doi:10.1056/NEJMoa1910836]

  • Agnelli, C; Valerio, M; Olmedo, M; Guinea, J; Zatarain-Nicolas, E; Del Carmen Martínez-Jiménez M; Alcala, L; Escribano, P; Cebollero Presmanes M; Bouza, E; Muñoz P; Martin-Rabadan, P.

    Fatal disseminated infection by Gymnascella hyalinospora in a heart transplant recipient

    Transplant Infectious Disease. 2019; 21(5): Nº de citas: 1 [doi:10.1111/tid.13128]

  • Farge, D; Frere, C; Connors, JM; Ay, C; Khorana, AA; Muno, ZA; Brenner, B; Kakkar, A; Rafii, H; Solymoss, S; Brilhante, D; Monreal, M; Bounameaux, H; Pabinger, I; Douketis, J; Int Initiative Thrombosis Canc ITA.

    2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    LANCET ONCOLOGY. 2019; 20(10): 566-581 Nº de citas: 779 [doi:10.1016/S1470-2045(19)30336-5]

  • Garcia-Carbonero, R; Marquez-Rodas, I; de la Cruz-Merino, L; Martinez-Trufero, J; Cabrera, MA; Piulats, JM; Capdevila, J; Grande, E; Martin-Algarra, S; Berrocal, A.

    Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    ONCOLOGIST. 2019; 24(10): 1375-1383 Nº de citas: 24 [doi:10.1634/theoncologist.2018-0718]

  • Cabezon-Gutierrez, L; Khosravi-Shahi, P; Palka-Kotlowska, M; Custodio-Cabello, S; Garcia-Martos, M.

    Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review of the Literature and a Single-center Experience

    Cureus Journal of Medical Science. 2019; 11(9): Nº de citas: 8 [doi:10.7759/cureus.5640]

  • Khosravi-Shahi, P; Cabezon-Gutierrez, L; Salcedo, MIA.

    State of art of advanced triple negative breast cancer

    Breast Journal. 2019; 25(5): 967-970 Nº de citas: 29 [doi:10.1111/tbj.13369]

  • Riechelmann, RP; Srimuninnimit, V; Bordonaro, R; Kavan, P; Di Bartolomeo, M; Maiello, E; Cicin, I; Garcia-Alfonso, P; Chau, I; Fedyanin, MY; Martos, CF; Ter-Ovanesov, M; Peeters, M; Ko, YJ; Yalcin, S; Karthaus, M; Aparicio, J; Heinemann, V; Picard, P; Bury, D; Drea, E; Sobrero, A.

    Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

    Clinical Colorectal Cancer. 2019; 18(3): 183 Nº de citas: 17 [doi:10.1016/j.clcc.2019.05.003]

  • Mulder, FI; Kraaijpoel, N; Di Nisio, M; Meyer, G; Mahe, I; Munoz, A; Bertoletti, L; Biosca, M; Maraveyas, A; Buller, HR; van Es, N.

    The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism

    THROMBOSIS RESEARCH. 2019; 181: 59-63 Nº de citas: 11 [doi:10.1016/j.thromres.2019.07.005]

  • Nathan, P; Ascierto, PA; Haanen, J; Espinosa, E; Demidov, L; Garbe, C; Guida, M; Lorigan, P; Chiarion-Sileni, V; Gogas, H; Maio, M; Fierro, MT; Hoeller, C; Terheyden, P; Gutzmer, R; Guren, TK; Bafaloukos, D; Rutkowski, P; Plummer, R; Waterston, A; Kaatz, M; Mandala, M; Marquez-Rodas, I; Munoz-Couselo, E; Dummer, R; Grigoryeva, E; Young, TC; Schadendorf, D.

    Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

    EUROPEAN JOURNAL OF CANCER. 2019; 119: 168-178 Nº de citas: 78 [doi:10.1016/j.ejca.2019.07.010]

  • Isla, D; De Las Penas, R; Insa, A; Marse, R; Martinez-Banaclocha, N; Mut, P; Moran, T; Sala, MA; Massuti, B; Ortega, AL; Jurado, JM; Gomez-Codina, J; Diz, P; Artal, A; Gutierrez, V; Vazquez, MF; Vinolas, N; Maestu, I; Camps, C; Alvarez, R; Soto, MAD; Ponce, S; Provencio, M.

    Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)

    LUNG CANCER. 2019; 135: 161-168 Nº de citas: 8 [doi:10.1016/j.lungcan.2018.11.041]